Complementary Roles of Endoscopic Ultrasound and CT/MRI in Pancreatic Lesions with Histopathological or Follow-Up Confirmation: A Retrospective Clinical and Imaging Analysis

Background: Differentiating benign from malignant pancreatic lesions requires integrating clinical, biochemical, and imaging data. We identified factors associated with malignancy and evaluated endoscopic ultrasound (EUS) alongside CT/MRI in pancreatic lesions with a reference diagnosis established by histopathology or clinical–radiological follow-up. Methods: In this single-center retrospective study (Sibiu, Romania; 2022–2025), all patients underwent EUS-guided FNA and CT and/or MRI. The reference standard was histopathology in 193 patients (82.1%) and clinical–radiological follow-up in 42 benign lesions (17.9%). Multivariable logistic regression identified factors associated with malignancy. EUS–CT/MRI agreement was assessed by concordance and Cohen’s kappa; diagnostic performance by sensitivity, specificity, predictive values, and Youden index. Results: Of 235 patients, 47 (20.0%) had malignant lesions. Age, ln-transformed CA 19-9, pancreatic duct dilation (OR 18.97; 95% CI 5.95–60.50), and lymphadenopathy were independently associated with malignancy (apparent AUC 0.956; optimism-corrected AUC 0.949 after internal bootstrap validation; no external validation). EUS visualized 46 lesions not detected on CT/MRI. Agreement was 95.8% for size category (κ = 0.905) and 87.8% for morphology (κ = 0.510). Sensitivity was 80.9% for both modalities; specificity 59.0% (EUS) and 51.6% (CT/MRI); Youden index 0.399 and 0.324. All 38 EUS-solid lesions were malignant (all adenocarcinoma) in this selected referral cohort. Conclusions: EUS detected additional lesions, but both modalities showed limited overall discrimination with comparable sensitivity. Findings support complementary use of EUS and CT/MRI within an integrated clinical assessment; the regression model requires validation. Predictive values apply to this selected referral cohort and may not be transferable to unselected populations.

Authors

Institutions

Publication Details

Journal
Life
Published
2026-10-22
DOI
https://doi.org/10.3390/life16111769
Primary Topic
Pancreatic and Hepatic Oncology Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Complementary Roles of Endoscopic Ultrasound and CT/MRI in Pancreatic Lesions with Histopathological or Follow-Up Confirmation: A Retrospective Clinical and Imaging Analysis

Cristian Ichim, Cosmin Ionuţ Lixandru, Adrian Boicean, Paula Anderco et al.
Life
Pancreatic and Hepatic Oncology Research
article

Complementary Roles of Endoscopic Ultrasound and CT/MRI in Pancreatic Lesions with Histopathological or Follow-Up Confirmation: A Retrospective Clinical and Imaging Analysis

Cristian Ichim, Cosmin Ionuţ Lixandru, Adrian Boicean, Paula Anderco, Corina Porr, Samuel Bogdan Todor, Livia Mirela Popa
article en

Abstract

Background: Differentiating benign from malignant pancreatic lesions requires integrating clinical, biochemical, and imaging data. We identified factors associated with malignancy and evaluated endoscopic ultrasound (EUS) alongside CT/MRI in pancreatic lesions with a reference diagnosis established by histopathology or clinical–radiological follow-up. Methods: In this single-center retrospective study (Sibiu, Romania; 2022–2025), all patients underwent EUS-guided FNA and CT and/or MRI. The reference standard was histopathology in 193 patients (82.1%) and clinical–radiological follow-up in 42 benign lesions (17.9%). Multivariable logistic regression identified factors associated with malignancy. EUS–CT/MRI agreement was assessed by concordance and Cohen’s kappa; diagnostic performance by sensitivity, specificity, predictive values, and Youden index. Results: Of 235 patients, 47 (20.0%) had malignant lesions. Age, ln-transformed CA 19-9, pancreatic duct dilation (OR 18.97; 95% CI 5.95–60.50), and lymphadenopathy were independently associated with malignancy (apparent AUC 0.956; optimism-corrected AUC 0.949 after internal bootstrap validation; no external validation). EUS visualized 46 lesions not detected on CT/MRI. Agreement was 95.8% for size category (κ = 0.905) and 87.8% for morphology (κ = 0.510). Sensitivity was 80.9% for both modalities; specificity 59.0% (EUS) and 51.6% (CT/MRI); Youden index 0.399 and 0.324. All 38 EUS-solid lesions were malignant (all adenocarcinoma) in this selected referral cohort. Conclusions: EUS detected additional lesions, but both modalities showed limited overall discrimination with comparable sensitivity. Findings support complementary use of EUS and CT/MRI within an integrated clinical assessment; the regression model requires validation. Predictive values apply to this selected referral cohort and may not be transferable to unselected populations.

LifeVol. 16(11)
Lucian Blaga University of Sibiu (RO), Transylvania University of Brașov (RO)
Openalex Percentile: Top 17%
Pancreatic and Hepatic Oncology Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon